ENGLEWOOD, Colo., Feb. 16, 2021 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical
company focused on the advancement of immunology-based therapies
for prevalent inflammatory conditions, announced that the Company
will present at The Microcap Rodeo Winter Wonderland Conference on
February 17, 2021 at 2:30pm EST. This conference is virtual.
To access the webcast, please log in to the following link
approximately 10 minutes prior to the start of the presentation
time: https://www.webcaster4.com/Webcast/Page/2134/40042.
About Ampio Pharmaceutical,
Inc.
Ampio Pharmaceuticals, Inc. is a development stage
biopharmaceutical company primarily focused on the development of
AmpionTM, our product candidate, to treat prevalent
inflammatory conditions for which there are limited treatment
options. Ampio's lead drug, AmpionTM, is backed by
an extensive patent portfolio with intellectual property protection
extending through 2032, and will be eligible for 12-year FDA market
exclusivity upon approval as a novel biologic under the biologics
price competition and innovation act ("BPCIA").
Forward Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to AmpionTM and its
classification, as well as those associated with regulatory
approvals and other FDA decisions, the Biological License
Application ("BLA"), the ability of Ampio to enter into
partnering arrangements, clinical trials and decisions and
changes in business conditions and similar events, the ability to
receive regulatory approval to conduct clinical trials, that
AmpionTM may be used to treat ARDS induced by COVID-19,
all of which are inherently subject to various risks and
uncertainties. The risks and uncertainties involved include those
detailed from time to time in Ampio's filings with the Securities
and Exchange Commission, including without limitation, under
Ampio's Annual Report on Form 10-K and other documents filed with
the Securities and Exchange Commission. Ampio undertakes no
obligation to revise or update these forward-looking statements,
whether as a result of new information, future events or
otherwise.
Company Contact
Investor Relations
Joe Hassett
joeh@gregoryfca.com
484-686-6600
Media Contact
Sarah May
sarahm@gregoryfca.com
215-205-1217
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-to-present-at-upcoming-investor-conference-301228759.html
SOURCE Ampio Pharmaceuticals, Inc.